Company or group introduction
Leiden Bio Science Park is described as one of Europe’s leading life sciences and health clusters, bringing together research, education, startups, scale-ups, and multinational companies within a single ecosystem.
Foundation year
1984
Location
Not discussed in the transcript.
Modality + therapeutic focus
Broad life sciences and health ecosystem including cell and gene therapy, infectious disease vaccines, personalised medicine, and data and AI applications.
About the speaker
Esther Peters is Director of Leiden Bio Science Park. She works across stakeholders including universities, hospitals, companies, and government to strengthen the innovation ecosystem and support the translation of scientific knowledge into business and patient impact.
The discussion with Esther focuses less on a single therapeutic program and more on the conditions required to move innovation through the system. If you are building a company or developing a therapy, the constraints she describes are not limited to science. They sit across regulation, funding, collaboration, and how effectively an ecosystem connects its own capabilities.
Intro
Moving a therapy from idea to patient is rarely limited by science alone. It depends on how well systems support long timelines, high costs, and complex collaboration. In this conversation, Esther reflects on what it takes to translate strong research into real-world impact within a dense life sciences ecosystem. Her perspective focuses on the structural constraints that shape whether innovation reaches patients.
Standalone quotes
• “From idea to product, it takes almost 15 years.”
• “These types of companies are facing a valley of death.”
• “You can never do this by yourself.”
From Scientific Strength to Patient Impact
Leiden Bio Science Park is structured to cover the full development spectrum, from early research to clinical translation and commercialisation. Esther emphasises that the presence of infrastructure and knowledge alone is not sufficient.
“It’s great to have all this knowledge here… but what we, in the end, achieve of course, is real impact in patients’ lives.”
The challenge is not generating ideas but translating them into viable products and companies. This requires coordinated effort across business development, talent development, and community building. For developers, this highlights a recurring reality. Progress depends not only on scientific quality but also on whether the surrounding system actively supports development at each stage.
This also shapes how the park defines its role. It is not simply a location but a mechanism for connecting people, aligning incentives, and enabling progression through the development pathway.
Time, Cost, and Structural Friction
When Esther describes the path from idea to product, the scale of the challenge becomes clear. “From idea to product, it takes almost 15 years.”
Alongside this timeline comes a significant financial burden. The combination creates a high-risk environment where delays compound quickly. For developers, this reinforces that timelines are not only scientific. They are shaped by regulatory processes, funding availability, and operational complexity.
Esther points to regulation as a major source of friction in Europe. While quality and safety are essential, she argues that additional layers of requirements slow progress without necessarily improving outcomes. “We are putting too much on top of it, and that we have too long a time.”
The consequence is not just delay. In some cases, it becomes difficult to reach the market at all. This creates a disconnect between scientific capability and patient access. For companies, this is not an abstract issue. It directly affects where and how development programs are advanced.
The Valley Between Innovation and Scale
Funding remains a central constraint, particularly in the transition from early development to later-stage validation. Esther describes this as a persistent structural gap rather than a temporary challenge.
“These types of companies are facing a valley of death, and we still don’t have the right instruments to support them in that fragile phase.”
Importantly, she notes that failure at this stage is often not due to weak science. Instead, it reflects an inability to sustain progress through capital-intensive phases. For developers, this suggests that planning for scale must begin early, well before clinical milestones.
The implication is that ecosystems need mechanisms that bridge this gap. Without them, prior investment in research is effectively lost. This shifts the focus from individual companies to system-level design.
Complexity as Both Strength and Constraint
The breadth of Leiden Bio Science Park is one of its defining characteristics. It includes capabilities across prevention, diagnostics, therapeutics, and enabling technologies such as data and AI.
This diversity creates opportunities for cross-disciplinary innovation, but it also introduces coordination challenges. Esther identifies connection between domains as an area where potential is not fully realised. “The challenge is to connect all these aspects better.”
For example, insights from biomarkers could inform prevention strategies, while social sciences could improve patient adoption of new technologies. These links exist within the ecosystem but are not always actively integrated.
If you are developing a therapy, this points to an often-overlooked factor. The value of an ecosystem depends not only on what is present, but on how effectively those elements interact.
Talent, Training, and Adaptability
Compared to funding and regulation, talent is less of a bottleneck within this ecosystem. Esther describes a layered education and training system that spans vocational training, applied sciences, and academic research.
A notable feature is the ability to retrain individuals from outside the life sciences sector. This includes programmes that prepare people for GMP environments and integrate them into the workforce. For companies, this reduces one barrier to scaling operations.
At the same time, there is a need to continuously update skills, particularly in data and AI. These capabilities are becoming embedded across the development process rather than remaining specialised functions.
The broader lesson is that talent pipelines must be both deep and flexible. Scaling innovation requires not only specialists but also systems that can adapt to changing technical demands.
Why This Session Matters
Esther’s perspective is shaped by her position at the centre of a large and interconnected ecosystem. Rather than focusing on a single therapy or technology, she highlights the structural conditions that determine whether innovation reaches patients.
Her insights are relevant if you are building within cell and gene therapy or adjacent fields. They point to recurring constraints that sit outside the lab but directly affect outcomes. These include regulatory design, funding continuity, and the ability to connect capabilities across disciplines.
Perhaps most importantly, her view reinforces that progress is collective. “You can never do this by yourself.”
For developers and decision-makers, this is less a statement about collaboration in principle and more a practical reality. The success of any single program depends on how well the surrounding system functions.
